Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus

被引:161
作者
Cui, LZ
Iwamoto, A
Lian, JQ
Neoh, HM
Maruyama, T
Horikawa, Y
Hiramatsu, K
机构
[1] Juntendo Univ, Dept Bacteriol, Fac Med, Bunkyo Ku, Tokyo 1138421, Japan
[2] Adv Sci Res Ctr, Tokai, Ibaraki 3191195, Japan
[3] Japan Atom Energy Res Inst, Tokai, Ibaraki 3191195, Japan
[4] Juntendo Univ, Fac Med, Dept Phys, Chiba 2701695, Japan
关键词
D O I
10.1128/AAC.50.2.428-438.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
As an aggressive pathogen, Staphylococcus aureus poses a significant public health threat and is becoming increasingly resistant to currently available antibiotics, including vancomycin, the drug of last resort for gram-positive bacterial infections. S. aureus with intermediate levels of resistance to vancomycin (vancomycin-intermediate S. aureus [VISA]) was first identified in 1996. The resistance mechanism of VISA, however, has not yet been clarified. We have previously shown that cell wall thickening is a common feature of VISA, and we have proposed that a thickened cell wall is a phenotypic determinant for vancomycin resistance in VISA (L. Cui, X. Ma, K. Sato, et al., J. Clin. Microbiol. 41:5-14, 2003). Here we show the occurrence of an anomalous diffusion of vancomycin through the VISA cell wall, which is caused by clogging of the cell wall with vancomycin itself. A series of experiments demonstrates that the thickened cell wall of VISA could protect ongoing peptidoglycan biosynthesis in the cytoplasmic membrane from vancomycin inhibition, allowing the cells to continue producing nascent cell wall peptidoglycan and thus making the cells resistant to vancomycin. We conclude that the cooperative effect of the clogging and cell wall thickening enables VISA to prevent vancomycin from reaching its true target in the cytoplasmic membrane, exhibiting a new class of antibiotic resistance in gram-positive pathogens.
引用
收藏
页码:428 / 438
页数:11
相关论文
共 51 条
[1]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P902
[2]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565
[3]   THE STRUCTURE AND MODE OF ACTION OF GLYCOPEPTIDE ANTIBIOTICS OF THE VANCOMYCIN GROUP [J].
BARNA, JCJ ;
WILLIAMS, DH .
ANNUAL REVIEW OF MICROBIOLOGY, 1984, 38 :339-357
[4]  
Bischoff M, 2001, FEMS MICROBIOL LETT, V194, P77, DOI 10.1016/S0378-1097(00)00509-7
[5]   A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates [J].
Boyle-Vavra, S ;
Labischinski, H ;
Ebert, CC ;
Ehlert, K ;
Daum, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :280-287
[6]   Cloning of the Staphylococcus aureus ddh gene encoding NAD(+)-dependent D-lactate dehydrogenase and insertional inactivation in a glycopeptide-resistant isolate [J].
BoyleVavra, S ;
deJonge, BLM ;
Ebert, CC ;
Daum, RS .
JOURNAL OF BACTERIOLOGY, 1997, 179 (21) :6756-6763
[7]   Vancomycin-resistant enterococci [J].
Cetinkaya, Y ;
Falk, P ;
Mayhall, CG .
CLINICAL MICROBIOLOGY REVIEWS, 2000, 13 (04) :686-+
[8]   Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals [J].
Chesneau, O ;
Morvan, A ;
El Solh, N .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) :887-890
[9]   Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus [J].
Cui, L ;
Ma, XX ;
Sato, K ;
Okuma, K ;
Tenover, FC ;
Mamizuka, EM ;
Gemmell, CG ;
Kim, MN ;
Ploy, MC ;
El Solh, N ;
Ferraz, V ;
Hiramatsu, K .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (01) :5-14
[10]  
Cui Longzhu, 2003, P187